• Lupuzor

    Aiming to deliver a safe treatment for Lupus sufferers

    Read more

  • Innovative peptide drug development

    For the benefit of patients worldwide

    Read more

  • ImmuPharma is one of the leading specialist drug development companies listed on AIM of the LSE

    Read more

Significant highlights

Pharmaceutical drug development

Focused on making patient lives better

ImmuPharma PLC is a pharmaceutical development company focusing on developing novel medicines in specialist markets with serious unmet need. Lupuzor™ is the company’s most advanced drug in development and is a treatment for lupus, a life threatening autoimmune disease and has now completed dosing Lupus patients in its Phase III pivotal trial. This is only part of our story as our scientists and researchers are developing drugs to make life changing difference to peoples lives worldwide.

We continue to work with our long term partner Centre National de la Recherche Scientifique (CNRS), Europe’s largest fundamental research institution and ImmuPharma’s long standing collaboration partner.

Developing Innovative Peptides

ImmuPharma PLC is a speciality biopharmaceutical company listed since 2006 on AIM of the London Stock Exchange (LSE:IMM). ImmuPharma discovers and develops peptide-based therapeutics.The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, Lupuzor™, is a first-in class autophagy immunomodulator which is in Phase III for the treatment of Lupus, a life threatening auto immune-disease. Preclinical analysis suggest that there are also opportunities around the therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action. ImmuPharma and Avion Pharmaceuticals signed on 29 November 2019, an exclusive licence and development agreement and trademark agreement for Lupuzor™, to fund a new international Phase III trial for Lupuzor™ and commercialise in the US. Further opportunities to enter into additional partnerships outside of the US for Lupuzor™ continue.  ImmuPharma is led by a commercially focused Board and management team with extensive experience.

Click here for further details on the License and Development Agreement with Avion Pharmaceuticals

News Updates

Share Price

Market Cap

ImmuPharma transforms care for people worldwide

Developing innovative drugs for serious medical conditions

Lead program for the potential breakthrough compound for Lupus, the life threatening auto-immune disease

With important insights gained from the first pivotal Phase III Lupuzor™ trial, a new optimised international Phase III clinical trial design has been identified with US partner Avion Pharmaceuticals.


Lupuzor™, is also known by its chemical name ‘Forigerimod’ or P140. ImmuPharma has the potential of expanding the P140 peptide platform into other auto immune conditions such as: CIDP, Rheumatoid Arthritis, Crohn’s Disease, and Asthma. Very few AIM-listed drug development companies have late-stage clinical assets of similar calibre.


ImmuPharma’s subsidiary ‘Ureka Pharma’ has initiated the development of a novel and innovative peptide technology platform through the collaboration with CNRS, gaining access to pioneering research centred on novel peptide drugs at the University of Bordeaux and the Institut Européen de Chimie et Biologie. Two therapeutics areas are being targeted. The first in diabetes and the most recent program is ‘BioGlucagon’, a product in development as a potential new rescue therapy for low sugar events (hypoglycaemia) in diabetes.


Despite the obvious threats to the health and wellbeing of the world’s population, anti-infectives is a therapy area that attracts one of the lowest R&D spends in the biopharma industry. So, this is an attractive therapy area for speed to market and lower cost of trials. ImmuPharma has recently developed three anti-infective programs, which are:


ImmuPharma’s IPP-204106, is a potential treatment for various cancers and acts by modulating angiogenesis (formation of new blood vessels) and proliferation (rapid reproduction). We are also investigating its use in age-related macular degeneration, diabetic retinopathy and other ophthalmological indications.

We are focused on advancing the care of patients suffering
from serious medical conditions worldwide.

Our headquarters are in London and our research centres are in France and Switzerland.

To contact us click here